Profile data is unavailable for this security.
About the company
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
- Revenue in USD (TTM)0.00
- Net income in USD-12.36m
- Incorporated2020
- Employees3.00
- LocationMira Pharmaceuticals Inc1200 Brickell Avenue, Suite 1950 #1183MIAMI 33131United StatesUSA
- Phone+1 (813) 369-5150
- Websitehttps://mirapharmaceuticals.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.72m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Molecular Templates Inc | 31.76m | -18.40m | 7.83m | 62.00 | -- | 1.09 | -- | 0.2467 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
National Graphite Corp | 0.00 | -1.97m | 7.87m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Protext Mobility Inc | 750.00 | -2.21m | 7.91m | 4.00 | -- | -- | -- | 10,549.47 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
ABVC Biopharma Inc | 25.37k | -12.62m | 7.92m | 16.00 | -- | 1.00 | -- | 312.25 | -2.37 | -2.37 | 0.0043 | 0.7284 | 0.002 | -- | 0.0673 | 1,585.63 | -103.15 | -103.38 | -189.31 | -231.54 | -854.20 | 76.25 | -51,218.29 | -2,019.89 | -- | -3.19 | 0.1853 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
NLS Pharmaceutics AG | 0.00 | -12.17m | 7.98m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
Pulmatrix Inc | 11.68m | -8.85m | 8.00m | 22.00 | -- | 0.4206 | -- | 0.6846 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
Weed Inc | 0.00 | -5.19k | 8.05m | 2.00 | -- | 74.91 | 205.59 | -- | -0.00001 | -0.00001 | 0.00 | 0.0009 | 0.00 | -- | -- | 0.00 | -0.4942 | -385.93 | -9.56 | -822.37 | -- | -- | -- | -- | -- | -23.03 | 0.5461 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Inhibikase Therapeutics Inc | 195.98k | -19.20m | 8.30m | 8.00 | -- | 1.10 | -- | 42.36 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
BioNexus Gene Lab Corp | 9.78m | -2.66m | 8.35m | 30.00 | -- | 0.8938 | -- | 0.8543 | -0.14 | -0.14 | 0.651 | 0.5289 | 1.01 | 8.55 | 5.80 | -- | -27.53 | -3.83 | -33.16 | -5.02 | 13.56 | 14.55 | -27.25 | -3.04 | 3.98 | -162.45 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
Moleculin Biotech Inc | 0.00 | -26.82m | 8.39m | 18.00 | -- | 0.3887 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
Mira Pharmaceuticals Inc | 0.00 | -12.36m | 8.50m | 3.00 | -- | 2.69 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
Plus Therapeutics Inc (USA) | 6.08m | -11.77m | 8.73m | 20.00 | -- | -- | -- | 1.43 | -3.19 | -3.19 | 1.67 | -1.13 | 0.5724 | -- | -- | 304,200.00 | -110.75 | -59.18 | -- | -133.04 | -- | -- | -193.49 | -470.45 | -- | -- | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 8.78m | 20.00 | -- | -- | -- | 675.58 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 9.34m | 389.00 | 0.0017 | 0.0002 | 1.01 | 0.1641 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Cross Staff Investments, Inc.as of 31 Mar 2024 | 383.40k | 2.59% |
Virtu Americas LLCas of 31 Mar 2024 | 63.06k | 0.43% |
Suncoast Equity Management LLCas of 31 Mar 2024 | 40.00k | 0.27% |
HRT Financial LLCas of 31 Mar 2024 | 30.65k | 0.21% |
Praetorian Wealth Management, Inc.as of 31 Mar 2024 | 27.50k | 0.19% |
XTX Markets LLCas of 31 Mar 2024 | 25.54k | 0.17% |
G1 Execution Services LLCas of 31 Mar 2024 | 15.57k | 0.11% |
Northern Trust Global Investments Ltd.as of 31 Mar 2024 | 10.23k | 0.07% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 10.23k | 0.07% |
Cary Street Partners Investment Advisory LLCas of 31 Mar 2024 | 10.00k | 0.07% |